Bio-Rad targets ~9% core revenue CAGR, 28% adj. EBITDA margin by 2025 at Investor Day

BIO-RAD LABORATORIES, INC.

Core revenue CAGR target of ~9% from 2021 to 2025, excluding COVID-related sales and currency effects.
Adjusted EBITDA margin target of 28% in 2025, up from 20%+ target set in 2017.
Previously set 2017 targets of 3-5% revenue growth and 20%+ EBITDA margin were exceeded.
Growth drivers include ddPCR, single cell analysis, biopharma expansion, and molecular diagnostics.
Capital allocation strategy includes generating cash flow and pursuing strategic acquisitions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.